<DOC>
	<DOCNO>NCT01031225</DOCNO>
	<brief_summary>This phase 2 study HSP90 inhibitor , STA-9090 ( ganetespib ) subject stage IIIB IV non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study HSP90 Inhibitor , STA-9090 Subjects With Stage IIIB IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Pathologically confirm diagnosis Stage IIIB ( pleural effusion ) Stage IV NSCLC measurable disease RECIST evidence progression Availability tissue analysis ECOG Performance Status 0 1 Adequate organ function define protocol . Must least 18 year old able willing sign write informed consent document Poor venous access require indwell catheter study drug administration Women pregnant lactate Ventricular ejection fraction &lt; = 55 % baseline Any uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA 9090</keyword>
	<keyword>ganetespib )</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>